Characteristic All women Regression Persistence Progression Progression
(N = 349) Normal (n = 301) LSIL (CIN1) (n = 23) CIN2 (n = 15) CIN3+ (n = 10)
Age (mean±SD), y 39.3±10.6 39.1±10.5 38.4±10.9 40.2±10.9 40.6±12.4
Age groups, n (%)
21-24 years 25 (7.2%) 20 (6.6%) 3 (13.0%) 1 (6.7%) 1 (10.0%)
≥25 years 324 (92.8%) 281 (93.4%) 20 (87.0%) 14 (93.3%) 9 (90.0%)
Cytology, n (%)
NILM 213 (61.0%) 192 (63.8%) 11 (47.8%) 5 (33.3%) 5 (50.0%)
ASC-US 58 (16.6%) 49 (16.3%) 3 (13.0%) 4 (26.7%) 2a (20.0%)
LSIL 78 (22.3%) 60 (19.9%) 9 (39.1%) 6 (40.0%) 3 (30.0%)
AHPV, n (%)
AHPV-GT+ 58 (16.6%) 43 (14.3%) 4 (17.4%) 6 (40.0%) 5 (50.0%)
HPV 16+ 37 (10.6%) 27 (9.0%) 2 (8.7%) 4 (26.7%) 4 (40.0%)
HPV 18/45+ 21 (6.0%) 16 (5.3%) 2 (8.7%) 2 (13.3%) 1a (10.0%)
AHPV-GT– 291 (83.4%) 258 (85.7%) 19 (82.6%) 9 (60.0%) 5 (50.0%)